HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th

SOUTHLAKE, TX / ACCESSWIRE / October 6, 2022 / Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) ("HeartSciences" or the "Company"), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois.

Mr. Simpson is scheduled to present on Wednesday, October 12th at 1:30 p.m. Central Time/2:30 p.m. Eastern Time. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2924/46700. Mr. Simpson will also be available for one-on-one meetings with qualified investors throughout the conference.

To receive additional information, request an invitation, or to schedule a one-on-one meeting, please email [email protected].

Investors can register for the conference here.

About the MicroCap Rodeo Conferences

The second-annual, live in-person MicroCap Rodeo is back. Join us as we go on the road and participate in the Windy City Roundup 2022 in Chicago, Illinois. Over two days in October, investors can harness top stocks for their portfolios. They'll meet with executive management teams from approximately 60-plus microcap companies across a wide variety of industries and gain an understanding into the key value drivers and potential trends for 2023. Complementing the interactive, in-depth 25-minute one-on-one meeting format will be four tracks of company presentations.

About HeartSciences

Heart Test Laboratories, Inc. d/b/a HeartSciences is medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical usefulness. The Company's objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences' first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista device and consumables for each test, is expected to be "razor-razorblade" as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required for every test performed.

For more information, please visit: https://www.heartsciences.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For investor and media inquiries, please contact:

Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: [email protected]

Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: [email protected]

SOURCE: Heart Test Laboratories, Inc. d/b/a HeartSciences